Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wharton's jelly stem cells, exosomes, and platelet-rich plasma for retinitis pigmentosa
IRCT20240706062337N2Phase 2Recruiting
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Apr 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of wharton's jelly stem cells and platelet-rich plasma in retinitis pigmentosa (RP) (3 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Visual acuity improvement, Visual field improvement and 5 more. Started Apr 2026; status: recruiting.
02
Drugs
wharton's jelly stem cellsplatelet-rich plasma
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on IRCT20240706062337N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240706062337N2.